Characterization of novel bacteriophage PSKP16 and its therapeutic potential against β-lactamase and biofilm producer strain of K2-Hypervirulent Klebsiella pneumoniae pneumonia infection in mice model

Rahimi, Sara; Bakht, Mehdi; Javadi, Amir; Foroughi, Farshad; Marashi, Seyed Mahmoud Amin; Nikkhahi, Farhad

doi:10.1186/s12866-023-02979-7

Table 1 The properties of thirty ESBL /CRKP K. pneumonia strains used in the study

From: Characterization of novel bacteriophage PSKP16 and its therapeutic potential against β-lactamase and biofilm producer strain of K2-Hypervirulent Klebsiella pneumoniae pneumonia infection in mice model

Isolat es	ESBL genotype	Carbapenemase genotype	MIC (mg/L) Colistin	MIC (mg/L) Tigecycline	MDR/XDR	Biofilm	String-test	Capsule serotype	CPS biosynthesis			Adhesion		siderophores
Isolat es	ESBL genotype	Carbapenemase genotype	MIC (mg/L) Colistin	MIC (mg/L) Tigecycline	MDR/XDR	Biofilm	String-test	Capsule serotype	rmpA	magA	wcaG	mrkD	fimH	entB	iroB	iutA	iucA	ybtS
KP1	SHV, CTX-M, TEM	OXA-48	2	0.5	MDR	Intermediate	+	K54			+	+	+	+
KP2	SHV, CTX-M, TEM		0.5	0.5	MDR	Strong	+	K1		+	+	+	+	+			+
KP3^a	SHV		0.5	0.25	MDR	Strong	+	K2	+			+	+	+	+	+	+	+
KP4	SHV, CTX-M, TEM		16	0.5	XDR	Strong	+	K2	+			+	+	+
KP5	SHV, CTX-M, TEM	OXA-48	0.5	0.5	XDR	Strong	+	K2				+	+	+
KP6	SHV, CTX-M, TEM		16	0.25	MDR	Strong	+	K1			+	+	+	+
KP7	SHV,TEM		0.5	0.5	MDR	Intermediate	-	K non-T				+	+
KP8	SHV, CTX-M, TEM		0.5	0.5	MDR	Strong	+	K1				+	+	+
KP9	SHV	OXA-48	0.5	0.25	MDR	Strong	+	K1	+	+		+	+	+	+	+
KP10	SHV, CTX-M, TEM		0.5	0.5	MDR	Weak	-	K non-T				+	+	+
KP11	SHV, TEM		0.5	0.5	XDR	Weak	-	K non-T				+	+	+
KP1^b	SHV, CTX-M, TEM	OXA-48	16	0.25	XDR	Strong	+	K2	+		+	+	+	+			+
KP13	SHV, CTX-M, TEM	OXA-48	0.5	0.5	XDR	Strong	+	K1		+		+	+	+
KP14	SHV, CTX-M, TEM	NDM-1	0.5	0.25	MDR	Intermediate	+	K2				+	+	+		+	+
KP1^a	SHV, CTX-M	OXA-48	0.5	0.5	XDR	Strong	+	K2				+	+	+
KP16	SHV		0.5	0.5	MDR	Weak	-	K non-T			+	+	+	+
KP17	SHV, TEM, CTX-M		0.5	0.25	XDR	Strong	+	K2				+	+	+
KP18	SHV, CTX-M	OXA-48	2	0.5	MDR	Intermediate	+	K20			+	+	+	+			+
KP19	SHV, TEM	NDM-1	0.5	0.5	MDR	Weak	-	K non-T				+	+				+
KP20	SHV, CTX-M, TEM		0.5	0.25	MDR	Weak	-	K non-T				+	+	+			+
KP21	SHV, CTX-M	OXA-48	8	0.25	XDR	Intermediate	+	K1				+	+	+
KP22	SHV, CTX-M, TE	OXA-48	1	0.5	XDR	Intermediate	+	K1				+	+	+		+
KP23	SHV, CTX-M	OXA-48	2	0.5	XDR	Strong	+	K1			+	+	+				+
KP24	SHV, CTX-M, TEM		0.5	0.5	MDR	Weak	-	K non-T				+	+
KP25a	SHV, CTX-M, TEM		2	0.5	XDR	Strong	+	K2			+	+	+	+		+	+
KP26	SHV, CTX-M, TEM	OXA-48	2	0.5	XDR	Strong	+	K2			+	+	+	+
KP27	SHV		1	0.5	MDR	Strong	+	K5			+	+	+			+	+	+
KP28	SHV,CTX-M		2	0.5	MDR	Intermediate	+	K2	+			+	+	+
KP29	SHV,CTX-M,TEM	OXA-48	2	0.5	MDR	Strong	+	K1				+	+	+
KP30	SHV		2	0.5	MDR	Intermediate	-	K20				+	+				+

CPS Capsular polysaccharide, K non-T Non type able capsule
^aFour out of 30 K. pneumoniae isolates that were infected by PSKP16
^bKP12 was used in this study

Back to article page

ISSN: 1471-2180

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Microbiology

Contact us